Back
1 minute read

Pause in Administration of Johnson and Johnson COVID-19 Vaccine

The FDA is recommending an immediate pause in the administration of the Johnson and Johnson COVID-19 vaccine due reports of six cases of a rare and serious clots.

The FDA is recommending an immediate pause in the administration of the Johnson and Johnson (Janssen) COVID-19 vaccine due reports of six cases of a rare and serious clot (cerebral venous sinus thrombosis)…there has been one associated death…for context, 6.8 million doses of the Johnson and Johnson COVID-19 vaccine have been administered…a link to the FDA statement is below.

Consequently, all CommonSpirit Health facilities should immediately halt administration of the Johnson and Johnson COVID-19 vaccine…there will be an emergency session of the Advisory Committee on Immunization Practices (ACIP) tomorrow (Wednesday, April 14) to review the data…additional guidance might be forthcoming after ACIP meets.

Please be sure all of your sites are aware of this development…our pharmacy and patient safety teams are working to provide additional information today.

Read the full story at the FDA Website.